Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Furmonertinib |
Trade Name | |
Synonyms | AST2818|AST2818|Alflutinib |
Drug Descriptions |
Furmonertinib (alflutinib) is a third-generation EGFR inhibitor that targets both EGFR activating mutations and T790M, potentially leading to tumor growth inhibition (PMID: 33780662, PMID: 35662408). |
DrugClasses | EGFR Inhibitor 3rd gen 26 |
CAS Registry Number | 1869057-83-9 |
NCIT ID | C180535 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Anlotinib + Furmonertinib | Anlotinib Furmonertinib | 0 | 0 |
Crizotinib + Furmonertinib | Crizotinib Furmonertinib | 0 | 0 |
Dabrafenib + Furmonertinib + Trametinib | Dabrafenib Furmonertinib Trametinib | 0 | 0 |
Furmonertinib | Furmonertinib | 0 | 2 |
Furmonertinib + Methotrexate | Furmonertinib Methotrexate | 0 | 0 |
Furmonertinib + Pemetrexed Disodium | Furmonertinib Pemetrexed Disodium | 0 | 0 |
Furmonertinib + Savolitinib | Furmonertinib Savolitinib | 0 | 0 |